Summary
Join Drs. Leonidas Tapias and Michael Krainock as they review the latest clinical data supporting the use of ctDNA for molecular residual disease (MRD) assessment in resectable NSCLC. Learn how MRD helps identify NSCLC patients who remain at high recurrence risk after surgery and detects recurrence before radiographic imaging. The webinar will conclude with a review of real-world case studies, practical considerations for implementing MRD testing in routine practice, and future directions for research.
Sponsored by Natera, Inc.
This is an industry-sponsored session. The scientific content of this webinar has been reviewed by STS. However, the opinions expressed in this webinar are those of the presenters and supporting organization, and they do not necessarily reflect the views of The Society of Thoracic Surgeons. Continuing medical education (CME) credit for this activity is not offered by STS. No endorsement by STS is intended or implied.
Moderator
Linda W. Martin, MD, MPH
University of Virginia, Thoracic and Cardiovascular Surgery
Charlottesville, VA
Speakers
Leonidas Tapias, MD
University Hospitals
Cleveland, OH
Michael Krainock, MD, PhD
Natera, Inc.
Las Vegas, NV